RxDoctor Payments Data

Rahul Loungani, MD

Advanced Heart Failure and Transplant Cardiology · Atlanta, GANPI 1295167955

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $31,778 of the $51,402 with a category attached, or 61.8%. 31 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 49.4% of the total. 2025 is the largest year on record at $33,364, more than ten times the $674 reported in 2021.

$51,402in general payments, 2019–2025

Across 285 payments — averaging $180.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$25K
  • AstraZeneca$21K
  • Abbott$787
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$563
  • Cvrx, Inc.$502
  • Boehringer Ingelheim$453
  • plus $3K from 25 others
$169,869in research payments, 2019–2025

Across 8 payments — averaging $21,234 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$84K
  • E.r. Squibb & Sons, L.L.C.$51K
  • Boston Scientific$35K

What the payments were for

  • Consulting fees$8,39816%
  • Speaking & faculty fees$31,77862%
  • Travel & lodging$4,1628%
  • Food & beverage$6,85713%
  • Education$2080%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,402 in reported general payments places this provider in the 75th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

See all advanced heart failure and transplant cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$136,321
Medicare patients
281
Services billed
1,311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis58$1,808,677
VyndaqelTafamidis Meglumine31$682,018
EntrestoSacubitril/Valsartan201$235,896
EliquisApixaban70$76,318
FarxigaDapagliflozin Propanediol52$67,491
JardianceEmpagliflozin48$65,992
Voriconazole29$21,213
Tacrolimus34$18,970
TradjentaLinagliptin16$12,771
Mycophenolic AcidMycophenolate Sodium13$7,903
Valganciclovir Hcl20$6,226
Mycophenolate Mofetil12$5,079
Torsemide87$2,157
Midodrine Hcl17$1,683
Metoprolol Succinate94$1,554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$356$2,567,013159 claims
NovartisEntresto$186$235,896201 claims
Boehringer IngelheimJardiance, Tradjenta$453$78,76364 claims
AstraZenecaFarxiga$21,094$67,49152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

Other advanced heart failure and transplant cardiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →